1. Home
  2. CYRX vs SGMT Comparison

CYRX vs SGMT Comparison

Compare CYRX & SGMT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo CryoPort Inc.

CYRX

CryoPort Inc.

HOLD

Current Price

$16.84

Market Cap

814.9M

Sector

Health Care

ML Signal

HOLD

Logo Sagimet Biosciences Inc. Series A

SGMT

Sagimet Biosciences Inc. Series A

HOLD

Current Price

$11.31

Market Cap

676.3M

Sector

N/A

ML Signal

HOLD

Company Overview

Basic Information
Metric
CYRX
SGMT
Founded
1999
2006
Country
United States
United States
Employees
1100
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
814.9M
676.3M
IPO Year
2008
2021

Fundamental Metrics

Financial Performance
Metric
CYRX
SGMT
Price
$16.84
$11.31
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
8
8
Target Price
$13.31
$26.13
AVG Volume (30 Days)
440.9K
899.9K
Earning Date
05-04-2026
05-14-2026
Dividend Yield
N/A
N/A
EPS Growth
156.22
N/A
EPS
N/A
N/A
Revenue
$176,177,000.00
$2,000,000.00
Revenue This Year
$11.06
N/A
Revenue Next Year
$8.45
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$7.61
$4.50
52 Week High
$17.20
$11.45

Technical Indicators

Market Signals
Indicator
CYRX
SGMT
Relative Strength Index (RSI) 61.56 65.15
Support Level $14.55 $6.60
Resistance Level $16.87 N/A
Average True Range (ATR) 0.55 0.53
MACD 0.10 -0.07
Stochastic Oscillator 86.56 91.61

Price Performance

Historical Comparison
CYRX
SGMT

About CYRX CryoPort Inc.

CryoPort Inc is a provider of integrated, temperature-controlled supply chain solutions for the life sciences industry, with a focus on supporting the cell and gene therapy market. The company provides services such as temperature-controlled logistics, biostorage, bioservices, cryopreservation solutions, and cryogenic systems manufacturing. It operates through two reportable segments: Life Sciences Services and Life Sciences Products. It generates the majority of its revenue from the Life Sciences Services segment.

About SGMT Sagimet Biosciences Inc. Series A

Sagimet Biosciences Inc a clinical-stage biopharmaceutical company developing novel therapeutics called fatty acid synthase (FASN) inhibitors that target dysfunctional metabolic and fibrotic pathways in diseases resulting from the overproduction of the fatty acid, palmitate. Its drug candidate, denifanstat, is an oral, once-daily pill and selective FASN inhibitor in development for the treatment of metabolic dysfunction-associated steatohepatitis (MASH), acne and select forms of cancer. Its second FASN inhibitor, TVB-3567, is a potent and selective small molecule FASN inhibitor in development for acne. It operates as a single business segment, developing and commercializing therapeutics for the treatment of MASH and other diseases where FASN plays a pathogenic role.

Share on Social Networks: